Table 2 Demographics of early-phase and post-phase subjects (study 2)
From: Proteome profiling of home-sampled dried blood spots reveals proteins of SARS-CoV-2 infections
Early phase, IgM+IgG− | Late phase, IgM−IgG+ | P-value | |
|---|---|---|---|
Sample numbers | 27 | 43 | |
Sex | |||
Female | 14 (51.9%) | 28 (65.1%) | 0.782 |
Male | 8 (29.6%) | 13 (30.2%) | |
Missing | 5 (18.5%) | 2 (4.7%) | |
Age groups | |||
20–29 | 3 (11.1%) | 6 (14.0%) | 0.432 |
30–39 | 6 (22.2%) | 3 (7.0%) | |
40–49 | 5 (18.5%) | 9 (20.9%) | |
50–59 | 3 (11.1%) | 10 (23.3%) | |
60–69 | 4 (14.8%) | 10 (23.3%) | |
70–74 | 1 (3.7%) | 3 (7.0%) | |
Missing | 5 (18.5%) | 2 (4.7%) | |
Flu-like symptoms | |||
No | 9 (33.3%) | 12 (27.9%) | 0.279 |
Yes, fever | 1 (3.7%) | 6 (14.0%) | |
Yes, mild | 6 (22.2%) | 14 (32.6%) | |
Yes, severe | 1 (3.7%) | 0 (0%) | |
Missing | 10 (37.0%) | 11 (25.6%) | |
Respiratory symptoms | |||
No | 15 (55.6%) | 28 (65.1%) | 0.842 |
Yes | 5 (18.5%) | 7 (16.3%) | |
Coughing | 1 (3.7%) | 2 (4.7%) | |
Difficulty breathing | 0 (0%) | 2 (4.7%) | |
Both | 0 (0%) | 2 (4.7%) | |
Missing | 6 (22.2%) | 2 (4.7%) | |
